| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues | |||||||||
23,713 | 14,762 | 13,355 | - | - | - | - | - | - | - |
Cost of goods sold | |||||||||
24,574 | 11,780 | 9,564 | - | - | - | - | - | - | - |
Revenues, net | |||||||||
- | - | - | 12,982 | 39,896 | 40,108 | 35,051 | 37,723 | 36,957 | 33,378 |
Cost of goods sold | |||||||||
- | - | - | 9,855 | 31,826 | 35,639 | 31,106 | 31,651 | 29,386 | 26,418 |
Gross profit (loss) | |||||||||
-861 | 2,982 | 3,791 | 3,127 | 8,070 | 4,469 | 3,945 | 6,072 | 7,571 | 6,960 |
Selling, general and administrative expenses | |||||||||
13,696 | 11,194 | 9,888 | 12,384 | 12,567 | 14,354 | 12,366 | 13,690 | 14,441 | 15,995 |
Depreciation and amortization | |||||||||
- | - | - | - | 1,779 | 2,879 | 1,249 | - | - | - |
Goodwill impairment | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Professional fees | |||||||||
- | - | - | - | - | - | - | - | 2,922 | 2,027 |
Impairment of property | |||||||||
- | - | - | - | - | - | 300 | 1,069 | 906 | 1,900 |
Impairment of intangible assets | |||||||||
- | - | - | - | - | - | - | - | 686 | 0 |
Recoveries from former customers | |||||||||
- | - | - | - | - | - | - | - | -1,800 | 0 |
Loss on disposal of property, plant and equipment | |||||||||
- | - | - | - | - | - | - | - | - | -943 |
Total operating expenses | |||||||||
- | - | - | - | 14,346 | 17,233 | 13,915 | 14,759 | 17,155 | 20,865 |
Operating loss | |||||||||
-14,557 | -8,212 | -6,097 | -9,257 | -6,276 | -12,764 | -9,970 | -8,687 | -9,584 | -13,905 |
Interest income | |||||||||
50 | 0 | - | - | 107 | 115 | 109 | 74 | 126 | 84 |
Other income (expense): | |||||||||
Interest expense - accreted on debt | |||||||||
- | - | - | - | 455 | - | - | - | - | - |
Interest expense - accreted on debt converted to equity | |||||||||
- | - | - | - | - | 6,323 | 0 | - | - | - |
Interest expense - other | |||||||||
- | - | - | - | 2,646 | 4,011 | 3,934 | - | - | - |
Interest expense | |||||||||
96 | 12 | 1,623 | 2,483 | - | - | - | 1,926 | 1,763 | 1,406 |
Other expense | |||||||||
16 | 25 | 182 | 0 | - | 599 | 373 | 237 | 464 | 78 |
Change in fair value of derivative warrant liabilities | |||||||||
- | - | 670 | 1,625 | 1,001 | -1,209 | -1,029 | 5,420 | 332 | - |
Loss on acquisition of controlling interest in Rice Rx | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Change in fair value of derivative warrant and conversion liabilities | |||||||||
- | - | - | - | - | - | - | - | - | -349 |
Financing expense | |||||||||
- | - | - | - | - | 2,072 | 564 | 2,184 | 0 | - |
Foreign currency exchange, net | |||||||||
- | - | - | - | -370 | -174 | -440 | -617 | -99 | -64 |
Loss on extinguishment of debt | |||||||||
- | - | -8,290 | 0 | -1,904 | -906 | -2,891 | -4,941 | 0 | - |
Gain on resolution of Irgovel purchase litigation | |||||||||
- | - | - | 1,598 | 0 | - | - | - | - | - |
Other income (expense) | |||||||||
- | - | - | - | -209 | - | - | - | - | - |
Other income | |||||||||
884 | 193 | 307 | 563 | - | 12 | 13 | 27 | 232 | 148 |
Total other income | |||||||||
822 | 156 | -9,118 | 1,303 | -4,476 | -15,167 | -9,109 | -4,384 | -1,636 | -1,665 |
Professional fees | |||||||||
- | - | - | - | - | - | - | - | - | 1,033 |
Total reorganization expenses | |||||||||
- | - | - | - | - | - | - | - | - | 1,033 |
Loss before income taxes | |||||||||
-13,735 | -8,056 | -15,215 | -7,954 | -10,752 | -27,931 | -19,079 | -13,071 | -11,220 | -16,603 |
Income tax benefit | |||||||||
0 | 45 | -5,030 | -1,824 | -176 | -1,304 | -1,439 | -1,935 | -345 | -935 |
Loss from continuing operations | |||||||||
-13,735 | -8,101 | -10,185 | -6,130 | - | - | - | - | - | - |
Loss from discontinued operations | |||||||||
-216 | 0 | 3,983 | -5,120 | - | - | - | - | - | - |
Net loss | |||||||||
-13,951 | -8,101 | -6,202 | -11,250 | -10,576 | -26,627 | -17,640 | -11,136 | -10,875 | -15,668 |
Less - Net loss attributable to noncontrolling interest in discontinued operations | |||||||||
- | - | -1,671 | -2,720 | - | - | - | - | - | - |
Net loss attributable to noncontrolling interest in Nutra SA | |||||||||
- | - | - | - | -2,308 | -3,598 | -2,619 | -1,627 | -776 | 0 |
Net loss attributable to RiceBran Technologies shareholders | |||||||||
- | - | -4,531 | -8,530 | -8,268 | -23,029 | -15,021 | -9,509 | -10,099 | -15,668 |
Less - Dividends on preferred stock, beneficial conversion feature | |||||||||
- | - | 778 | 551 | 0 | - | - | - | - | - |
Net loss attributable to RiceBran Technologies common shareholders | |||||||||
- | - | -5,309 | -9,081 | -8,268 | - | - | - | - | - |
Basic loss per common share: | |||||||||
Continuing operations (in dollars per share) | |||||||||
-0.42 | -0.37 | -0.92 | -0.72 | - | - | - | - | - | - |
Discontinued operations (in dollars per share) | |||||||||
-0.01 | 0.00 | 0.47 | -0.25 | - | - | - | - | - | - |
Basic loss per common share (in dollars per share) | |||||||||
-0.43 | -0.37 | -0.45 | -0.97 | -0.90 | -3.96 | -12.95 | -9.29 | -0.05 | -0.08 |
Diluted loss per common share: | |||||||||
Continuing operations (in dollars per share) | |||||||||
-0.42 | -0.37 | -0.92 | -0.72 | - | - | - | - | - | - |
Discontinued operations (in dollars per share) | |||||||||
-0.01 | 0.00 | 0.47 | -0.25 | - | - | - | - | - | - |
Diluted loss per common share (in dollars per share) | |||||||||
-0.43 | -0.37 | -0.45 | -0.97 | -0.90 | -3.96 | -12.95 | -9.29 | -0.05 | -0.08 |
Weighted average number of shares outstanding: | |||||||||
Basic (in shares) | |||||||||
32,359 | 22,099 | 11,923 | 9,338 | 9,187 | 5,809 | 1,160 | 1,023 | 198,370 | 193,196 |
Diluted (in shares) | |||||||||
32,359 | 22,099 | 11,923 | 9,338 | 9,187 | 5,809 | 1,160 | 1,023 | 198,370 | 193,196 |